financetom
Business
financetom
/
Business
/
Nasdaq profit beats estimates as fintech sales soar
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Nasdaq profit beats estimates as fintech sales soar
Jul 25, 2024 4:36 AM

(Reuters) - Nasdaq beat estimates for second-quarter profit on Thursday, driven mainly by strong demand for its products that help traders navigate compliance requirements and safeguard against financial crimes.

To create a more steady and sustainable source of revenue, the transatlantic exchange operator has expanded beyond trading and listings and bolstered its financial technology unit.

Revenue from the unit soared nearly 79% to $420 million in the second quarter, while revenue from its index business jumped 29% to $167 million.

Net revenue jumped 25% to $1.16 billion. Analysts on average had expected $1.13 billion, according to LSEG data.

The company's adjusted profit of 69 cents per share also beat analysts' expectations of 64 cents.

A resilient economy has also prompted a surge in new listings on U.S. exchanges after a slowdown that lasted nearly two years.

A total of 84 companies listed its shares on the exchange in the second quarter ended June 30 compared with 62 from a year ago.

U.S. equity matched shares volumes jumped to 119.3 billion in the second quarter from 113.7 billion a year earlier. U.S. equity options volumes also rose to 42.1 million contracts from 39.2 million contracts.

(Reporting by Jaiveer Singh Shekhawat in Bengaluru; Editing by Shinjini Ganguli and Saumyadeb Chakrabarty)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
TIMELINE-Germany's Commerzbank has a bumpy history with big M&A
TIMELINE-Germany's Commerzbank has a bumpy history with big M&A
Sep 21, 2024
(Updates timeline originally published on Sept. 11 with latest developments) By Tom Sims FRANKFURT, Sept 18 (Reuters) - Commerzbank is poised to put CFO Bettina Orlopp in charge of talks with UniCredit when the German bank's supervisory board meets next week, two people with knowledge of the matter said, as the Italian rival considers a takeover. Commerzbank has, like some...
Musk's Neuralink gets FDA's breakthrough device tag for 'Blindsight' implant
Musk's Neuralink gets FDA's breakthrough device tag for 'Blindsight' implant
Sep 21, 2024
(Reuters) -Elon Musk's brain-chip startup Neuralink said on Tuesday its experimental implant aimed at restoring vision received the U.S. Food and Drug Administration's breakthrough device designation. The FDA's breakthrough tag is given to certain medical devices that provide treatment or diagnosis of life-threatening conditions. It is aimed at speeding up development and review of devices currently under development. The experimental...
Germany's Commerzbank has a bumpy history with big M&A
Germany's Commerzbank has a bumpy history with big M&A
Sep 21, 2024
FRANKFURT (Reuters) -Commerzbank is poised to put CFO Bettina Orlopp in charge of talks with UniCredit when the German bank's supervisory board meets next week, two people with knowledge of the matter said, as the Italian rival considers a takeover. Commerzbank has, like some other banks, had a rocky history with big mergers and acquisitions over the years. These are...
Vivos Therapeutics Says It Is Poised To Disrupt Pediatric Sleep Apnea Market, Secures FDA Approval For DNA Appliance To Treat Snoring In Children
Vivos Therapeutics Says It Is Poised To Disrupt Pediatric Sleep Apnea Market, Secures FDA Approval For DNA Appliance To Treat Snoring In Children
Sep 21, 2024
On Wednesday, the FDA granted 510(k) clearance to Vivos Therapeutics, Inc.’s flagship oral medical device, which is used to treat moderate to severe obstructive sleep apnea (OSA) and snoring in children. Recent published studies report up to 10.1 million U.S. children (ages 6-17) are estimated to suffer from pediatric OSA. Vivos’ DNA appliance is non-invasive, safe, comfortable, affordable, and highly effective....
Copyright 2023-2026 - www.financetom.com All Rights Reserved